Page 102 - Программа - Всероссийский конгресс с международным участием «Нейронауки: интеграция теории и практики», 18-19 ноября 2022 года, Онлайн

Известия Российской
НАУЧНЫЕ ОБЗОРЫ Том 41, № 4, 2022 Военно-медицинской академии
451
3. Gómez-Mesa J.E., Galindo-Coral S., Montes M.C., Muñoz Martin A.J. 18. Al-Aly Z., Xie Y. Bowe B. High-dimensional characterization of
Thrombosis and Coagulopathy in COVID-19 // Curr. Probl. Cardiol. post-acute sequelae of COVID-19 // Nature. 2021. Vol. 594, No. 7862.
2021. Vol. 46, No. 3. P. 100742. DOI: 10.1016/j.cpcardiol.2020.100742 P. 259–264. DOI: 10.1038/s41586-021-03553-9
4. Sachdeva M. Gianotti R., Shah M., et al. Cutaneous mani- 19. Dotan A., Muller S., Kanduc D., et al. The SARS-CoV-2 as an
festations of COVID-19: Report of three cases and a review instrumental trigger of autoimmunity // Autoimmun. Rev. 2021.
of literature // J. Dermatol. Sci. 2020. Vol. 98, No. 2. P. 75–81. Vol. 20, No. 4. P. 102792. DOI: 10.1016/j.autrev.2021.102792
DOI: 10.1016/j.jdermsci.2020.04.011 20. Baranzini S.E., Wang J., Gibson R.A., et al. Genome-wide as-
5. Seah I., Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) sociation analysis of susceptibility and clinical phenotype in mul-
Affect the Eyes? A Review of Coronaviruses and Ocular Implications tiple sclerosis // Hum. Mol. Genet. 2009. Vol. 18, No. 4. P. 767–778.
in Humans and Animals // Ocul. Immunol. Inflamm. 2020. Vol. 28, DOI: 10.1093/hmg/ddn388
No. 3. P. 391–395. DOI: 10.1080/09273948.2020.1738501 21. Lourenço C.M., Dupré N., Rivière J.B., et al. Expanding the differ-
6. Espíndola O.M., Gomes Y.C.P., Brandão C.O., et al. Inflamma- ential diagnosis of inherited neuropathies with non-uniform conduc-
tory Cytokine Patterns Associated with Neurological Diseases in tion: Andermann syndrome // J. Peripher. Nerv. Syst. 2012. Vol. 17,
Coronavirus Disease 2019 // Ann. Neurol. 2021. Vol. 89, No. 5. No. 1. P. 123–127. DOI: 10.1111/j.1529-8027.2012.00374.x
P. 1041–1045. DOI: 10.1002/ana.26041 22. Song E., Bartley C.M., Chow R.D., et al. Divergent and self-reac-
7. Bernard-Valnet R., Perriot S., Canales M., et al. Encephalopa- tive immune responses in the CNS of COVID-19 patients with neu-
thies Associated With Severe COVID-19 Present Neurovascular Unit rological symptoms // Cell Rep. Med. 2021. Vol. 2, No. 5. P. 100288.
Alterations Without Evidence for Strong Neuroinflammation // Neu- DOI: 10.1016/j.xcrm.2021.100288
rol. Neuroimmunol. Neuroinflamm. 2021. Vol. 8, No. 5. Art. e1029. 23. Xiao M,. Zhang Y., Zhang S., et al. Antiphospholipid Antibodies
DOI: 10.1212/nxi.0000000000001029 in Critically Ill Patients With COVID-19 // Arthritis. Rheumatol. 2020.
8. Moody R., Wilson K., Flanagan K.L., et al. Adaptive Immunity and Vol. 72, No. 12. P. 1998–2004. DOI: 10.1002/art.41425
the Risk of Autoreactivity in COVID-19 // Int. J. Mol. Sci. 2021. Vol. 22, 24. Bertin D., Brodovitch A., Beziane A., et al. Anticardiolipin IgG
No. 16. Art. 8965. DOI: 10.3390/ijms22168965 Autoantibody Level Is an Independent Risk Factor for COVID-19 Se-
9. Guan W.J., Ni Z.Y., Hu Y., et al. Clinical Characteristics of Corona- verity // Arthritis. Rheumatol. 2020. Vol. 72, No. 11. P. 1953–1955.
virus Disease 2019 in China // N. Engl. J. Med. 2020. Vol. 382, No. 18. DOI: 10.1002/art.41409
P. 1708–1720. DOI: 10.1056/nejmoa2002032 25. Wang E.Y., Mao T., Klein J., et al. Diverse Functional Autoantibod-
10. Chou S.H., Beghi E., Helbok R., et al. Global Incidence of Neuro- ies in Patients with COVID-19 // Nature. 2021. Vol. 595, No. 7866.
logical Manifestations Among Patients Hospitalized With COVID-19-A P. 283–288. DOI: 10.1101/2020.12.10.20247205
Report for the GCS-NeuroCOVID Consortium and the ENERGY 26. Woodruff M.C., Ramonell R.P., Nguyen D.C., et al. Extrafollicular
Consortium // JAMA Netw. Open. 2021. Vol. 4, No. 5. Art. e2112131. B cell responses correlate with neutralizing antibodies and morbidity
DOI: 10.1001/jamanetworkopen.2021.12131 in COVID-19 // Nat. Immunol. 2020. Vol. 21, No. 12. P. 1506–1516.
11. Ariño H., Heartshorne R., Michael B.D., et al. Neuroimmune dis- DOI: 10.1038/s41590-020-00814-z
orders in COVID-19 // J. Neurol. 2022. Vol. 269, No. 6. P. 2827–2839. 27. Jenks S.A., Cashman K.S., Zumaquero E., et al. Distinct Effec-
DOI: 10.1007/s00415-022-11050-w tor B Cells Induced by Unregulated Toll-like Receptor 7 Contribute
12. Liu J.M., Tan B.H., Wu S., et al. Evidence of central nervous sys- to Pathogenic Responses in Systemic Lupus Erythematosus //
tem infection and neuroinvasive routes, as well as neurological in- Immunity. 2018. Vol. 49, No. 4. P. 725–739.e6. DOI: 10.1016/j.im-
volvement, in the lethality of SARS-CoV-2 infection // J. Med. Virol. muni.2018.08.015. Erratum in: Immunity. 2020. Vol. 52, No. 1. P. 203.
2021. Vol. 93, No. 3. P. 1304–1313. DOI: 10.1002/jmv.26570 DOI: 10.1016/j.immuni.2019.12.005
13. Arbour N., Ekandé S., Côté G., et al. Persistent infection of 28. Latorre D. Autoimmunity and SARS-CoV-2 infection: Unraveling
human oligodendrocytic and neuroglial cell lines by human coro- the link in neurological disorders // Eur. J. Immunol. 2022. Vol. 52,
navirus 229E // J. Virol. 1999. Vol. 73, No. 4. P. 3326–3337. No. 10. P. 1561–1571. DOI: 10.1002/eji.202149475
DOI: 10.1128/jvi.73.4.3326-3337.1999 29. Garg R.K., Paliwal V.K., Gupta A. Spinal cord involvement in
14. Sarwar S., Rogers S., Mohamed A.S., et al. Multiple Scle- COVID-19: A review // J. Spinal. Cord. Med. 2021. Vol. 11. P. 1–15.
rosis Following SARS-CoV-2 Infection: A Case Report and Lit- DOI: 10.1080/10790268.2021.1888022
erature Review // Cureus. 2021. Vol. 13, No. 10. Art. e19036. 30. West T.W., Hess C., Cree B.A. Acute transverse myelitis: demy-
DOI: 10.7759/cureus.19036 elinating, inflammatory, and infectious myelopathies // Semin. Neu-
15. Fleischer M., Köhrmann M., Dolff S., et al. Observational co- rol. 2012. Vol. 32, No. 2. P. 97–113. DOI: 10.1055/s-0032-1322586
hort study of neurological involvement among patients with 31. Román G.C., Gracia F., Torres A., et al. Acute Transverse Myeli-
SARS-CoV-2 infection // Ther. Adv. Neurol. Disord. 2021. Vol. 14. tis (ATM): Clinical Review of 43 Patients With COVID-19-Associated
Art. 1756286421993701. DOI: 10.1177/175628642199370 ATM and 3 Post-Vaccination ATM Serious Adverse Events With the
16. Jarius S., Pache F., Körtvelyessy P., et al. Cerebrospinal fluid ChAdOx1 nCoV-19 Vaccine (AZD1222). // Front. Immunol. 2021.
findings in COVID-19: a multicenter study of 150 lumbar punctures Vol. 12. P. 653786. DOI: 10.3389/fimmu.2021.653786
in 127 patients // J. Neuroinflammation. 2022. Vol. 19, No. 1. P. 19. 32. Козлова А.О., Елисеева Д.Д., Симанив Т.О., и др. Аутоиммунные
DOI: 10.1186/s12974-021-02339-0 поражения спинного мозга, ассоциированные с новой коронавирус-
17. Remsik J., Wilcox J.A., Babady N.E., et al. Inflammatory Lep- ной инфекцией // Неврология, нейропсихиатрия, психосоматика.
tomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in 2022. № 14 (Прил. 1). C. 21–28. DOI: 10.14412/2074-2711-2022.1S-21-28
Cancer Patients // Cancer Cell. 2021. Vol. 39, No. 2. Art. 276–283.e3. 33. Ramanathan S., Mohammad S., Tantsis E., et al. Clinical course,
DOI: 10.1016/j.ccell.2021.01.007 therapeutic responses and outcomes in relapsing MOG antibody-
DOI: https://doi.org/10.17816/rmmar111889